Identification of a Primary Target of Thalidomide Teratogenicity
The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Thalidomide Teratogenicity Target: In the late 1950s and early 1960s, thalidomide was prescribed to pregnant women as a cure for morning sickness, but it was then found to have developmental defects, most obviously, stunted limbs in thousands of babies. Although its use was banned worldwide, thalidomide has since been found to be a valuable treatment for a range of cancers, inflammatory disorders, and leprosy. Several hypotheses have been proposed, but the mechanism of action of thalidomide is unknown. Using zebrafish and chicken as animal models, Ito et al. (p. 1345 ) show that the protein cereblon is a primary target of thalidomide. Thalidomide exerts teratogenic effects by binding to cereblon and inhibiting associated enzymatic activity important for limb development. Knowing the mechanism of action of thalidomide should encourage the search for thalidomide derivatives without teratogenic activity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IMiDs bind to cereblon and activate cereblon E3 ligase activity, resulting in the rapid ubiquitination and degradation of two specific B cell transcription factors, Ikaros family zinc finger proteins Ikaros (IKZF 1) and Aiolos (IKZF3).77–79”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [77]
In the citing paper
“Cereblon (CRBN), a substrate receptor for the cullin–RING ubiquitin ligase 4 (CRL4) complex, is a direct protein target for thalidomide teratogenicity and antitumor activity of immunomodulatory drugs (IMiDs).”
From Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon (2016) · cites this paper as Ito et al., 2010
In the citing paper
“FlagCRBN-W386E and FlagCRBN-W400E, and the double point mutant FlagCRBN-Y384A/W386A (FlagCRBN-YW/AA, which is defective in IMiD binding (Ito et al., 2010; Lopez-Girona et al., 2012)) failed to bind endogenous GS (Figure 6C).”
From Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon (2016) · cites this paper as Ito et al., 2010
In the citing paper
“The catastrophe was not a failure of pharmacokinetic scaling. Rather, the rodent species used for the original toxicology programs were largely resistant to thalidomide teratogenicity, while rabbits and primates are sensitive.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [55]
In the citing paper
“The case directly drove the development of ICH S5 reproductive toxicology guidelines mandating evaluation in two species, typically one rodent and one non-rodent, and underlies the broader principle that species panels for toxicodynamic endpoints must be selected on mechanistic grounds rather than convention [55,56].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [55]
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Effective targeted gene ‘knockdown’ in zebrafish
Nasevicius, A., & Ekker, S. C. (2000) · Nature Genetics · doi:10.1038/79951 · Cited by 2,483
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Sonic hedgehog mediates the polarizing activity of the ZPA
Riddle, R. D., Johnson, R. L., Laufer, E., & Tabin, C. (1993) · Cell · doi:10.1016/0092-8674(93)90626-2 · Cited by 2,307
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., & Kaplan, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1675 · Cited by 1,045
Groisman, R., Polanowska, J., Kuraoka, I., Sawada, J.-I., Saijo, M., Drapkin, R., Kisselev, A. F., Tanaka, K., & Nakatani, Y. (2003) · Cell · doi:10.1016/s0092-8674(03)00316-7 · Cited by 744
Back to the Future with Ubiquitin
Pickart, C. M. (2004) · Cell · doi:10.1016/s0092-8674(03)01074-2 · Cited by 697
Molecular architecture and assembly of the DDB1–CUL4A ubiquitin ligase machinery
Angers, S., Li, T., Yi, X., MacCoss, M. J., Moon, R. T., & Zheng, N. (2006) · Nature · doi:10.1038/nature05175 · Cited by 674
Jin, J., Arias, E. E., Chen, J., Harper, J. W., & Walter, J. C. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.08.010 · Cited by 632
Cited by
Items 701–800 of 1,003
Molecular glue degraders: exciting opportunities for novel drug discovery
Lemaitre, T., Cornu, M., Schwalen, F., Since, M., Kieffer, C., & Voisin-Chiret, A. S. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2306845 · Cited by 36
“They showed that thalidomide is able to bond to the E3 ligase CRBN and inhibit the associated enzymatic activity essential of the limbs development, responsible for its teratogenic effect [27], which is partly due to its chirality.”
BackgroundProtein degraders - from thalidomide to new PROTACs
Ito, T. (2023) · The Journal of Biochemistry · doi:10.1093/jb/mvad113 · Cited by 36
Self-citationFrom PROTAC to TPD: Advances and Opportunities in Targeted Protein Degradation
Wang, S., He, F., Tian, C., & Sun, A. (2024) · Pharmaceuticals · doi:10.3390/ph17010100 · Cited by 36
Sabbah, D. A., Hajjo, R., Bardaweel, S. K., & Zhong, H. A. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2338100 · Cited by 36
Expanding the ligand spaces for E3 ligases for the design of protein degraders
Saleem, R. S. Z., Schwalm, M. P., & Knapp, S. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117718 · Cited by 36
A pan-KRAS degrader for the treatment of KRAS-mutant cancers
Yang, J., Wang, Q.-L., Wang, G., Ye, J.-C., Li, Z.-Q., Wang, J.-Y., Liang, Z., Li, S., Sun, C., Liao, W., et al. (2024) · Cell Discovery · doi:10.1038/s41421-024-00699-4 · Cited by 36
Translating the anti-myeloma activity of Natural Killer cells into clinical application
Fionda, C., Stabile, H., Molfetta, R., Soriani, A., Bernardini, G., Zingoni, A., Gismondi, A., Paolini, R., Cippitelli, M., & Santoni, A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.10.005 · Cited by 36
Ubiquitination and Ubiquitin-Like Modifications in Multiple Myeloma: Biology and Therapy
Wirth, M., Schick, M., Keller, U. B., & Krönke, J. (2020) · Cancers · doi:10.3390/cancers12123764 · Cited by 36
Ligand-induced degrons for studying nuclear functions
Kanemaki, M. T. (2022) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2021.12.006 · Cited by 36
Selective Wee1 degradation by PROTAC degraders recruiting VHL and CRBN E3 ubiquitin ligases
Aublette, M. C., Harrison, T. A., Thorpe, E. J., & Gadd, M. S. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128636 · Cited by 35
Design and Development of IKZF2 and CK1α Dual Degraders
Miyamoto, D. K., Curnutt, N. M., Park, S., Stavropoulos, A., Kharas, M. G., & Woo, C. M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01736 · Cited by 35
Targeted protein degradation in CNS disorders: a promising route to novel therapeutics?
Kuemper, S., Cairns, A. G., Birchall, K., Yao, Z., & Large, J. M. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1370509 · Cited by 35
Novel approaches to map small molecule–target interactions
Kapoor, S., Waldmann, H., & Ziegler, S. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.05.020 · Cited by 35
Tan, L., & Gray, N. S. (2018) · Chinese Journal of Chemistry · doi:10.1002/cjoc.201800293 · Cited by 35
In vitro secondary pharmacological profiling: An IQ-DruSafe industry survey on current practices
Valentin, J., Guillon, J.-M., Jenkinson, S. G., Kadambi, V. J., Peri, R., Roberts, S., Ribeiro, L. R., Schmidt, F., & Armstrong, D. (2018) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2018.07.001 · Cited by 35
Bassoon inhibits proteasome activity via interaction with PSMB4
Montenegro‐Venegas, C., Fieńko, S., Anni, D., Pina-Fernández, E., Frischknecht, R., & Fejtová, A. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03590-z · Cited by 35
Discovery of Molecular Glue Degraders via Isogenic Morphological Profiling
Ng, A., Offensperger, F., Cisneros, J. A., Scholes, N. S., Malik, M., Villanti, L., Rukavina, A., Ferrada, E., Hannich, J. T., Koren, A., et al. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.3c00598 · Cited by 35
Investigational targeted therapies for the treatment of testicular germ cell tumors
Oing, C., Kollmannsberger, C., Oechsle, K., & Bokemeyer, C. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1195808 · Cited by 35
Progressing neurobiological strategies against proteostasis failure: Challenges in neurodegeneration
Amanullah, A., Upadhyay, A., Joshi, V., Mishra, R., Jana, N. R., & Mishra, A. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.08.005 · Cited by 35
In Vivo Formation of a Glutathione Conjugate Derived from Thalidomide in Humanized uPA-NOG Mice
Yamazaki, H., Suemizu, H., Igaya, S., Shimizu, M., Shibata, N., Nakamura, M., Chowdhury, G., & Guengerich, F. P. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200005g · Cited by 34
Chemical proteomics: terra incognita for novel drug target profiling
Huang, F., Zhang, B., Zhou, S., Zhao, X., Bian, C., & Wei, Y. (2012) · 癌症:英文版 · doi:10.5732/cjc.011.10377 · Cited by 34
Ege, N., Bouguenina, H., Tatari, M. N., & Chopra, R. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.02.011 · Cited by 34
Can preclinical drug development help to predict adverse events in clinical trials?
Chi, L. H., Burrows, A. D., & Anderson, R. L. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.08.010 · Cited by 34
Charliński, G., Vesole, D. H., & Jurczyszyn, A. J. (2021) · Cancers · doi:10.3390/cancers13184666 · Cited by 34
Chemical biology and pharmacology of histone lysine methylation inhibitors
Barghout, S. H., Machado, R. A. C., & Baršytė-Lovejoy, D. (2022) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2022.194840 · Cited by 34
Miñarro-Lleonar, M., Bertran‐Mostazo, A., Duro, J., Barril, X., & Juárez‐Jiménez, J. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01692 · Cited by 34
Affinity purification in target identification: the specificity challenge
Zheng, W., Li, G., & Li, X. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0635-2 · Cited by 34
Chemistry-based functional proteomics for drug target deconvolution
Wang, K., Yang, T., Wu, Q., Zhao, X., Nice, E. C., & Huang, C. (2012) · Expert Review of Proteomics · doi:10.1586/epr.12.19 · Cited by 34
Gandhi, A. K., Shi, T., Li, M., Jungnelius, U., Romano, A., Tabernero, J. M., Siena, S., Schafer, P. H., & Chopra, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080437 · Cited by 34
Chemical ‘Jekyll and Hyde’s: small-molecule inhibitors of developmental signaling pathways
Sakata, T., & Chen, J. (2011) · Chemical Society Reviews · doi:10.1039/c1cs15019g · Cited by 34
Bolomsky, A., Schreder, M., Meißner, T., Hose, D., Ludwig, H., Pfeifer, S., & Zojer, N. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.03.005 · Cited by 34
Chemical Metabolic Inhibitors for the Treatment of Blood-Borne Cancers
Villalba, M., López-Royuela, N., Krzywińska, E., Rathore, M. G., Hipskind, R. A., Haouas, H., & Allende-Vega, N. (2014) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/18715206113136660374 · Cited by 34
PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4
Ueno, N., Nishimura, N., Ueno, S., Endo, S., Tatetsu, H., Hirata, S., Hata, H., Matsuoka, M., Mitsuya, H., & Okuno, Y. (2017) · Oncogene · doi:10.1038/onc.2017.79 · Cited by 34
Applications of proteomics in pharmaceutical research and development
Yokota, H. (2018) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2018.05.008 · Cited by 34
Kamuf, M., & Trapp, O. (2010) · Chirality · doi:10.1002/chir.20885 · Cited by 34
Identification and characterization of cancer vulnerabilities via targeted protein degradation
Mayor-Ruiz, C., & Winter, G. E. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2018.12.003 · Cited by 33
SuFEx-based chemical diversification for the systematic discovery of CRBN molecular glues
Carter, T. R., Milosevich, N., Dada, L., Shaum, J. B., Sharpless, K. B., Kitamura, S., & Erb, M. A. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117699 · Cited by 33
PROTAC: a revolutionary technology propelling small molecule drugs into the next golden age
Cai, J., Chen, C., Wang, J., Zhang, X., Cui, Y., Zhu, Q., & Sun, H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1676414 · Cited by 33
Shindiapina, P., Brown, J. R., & Danilov, A. V. (2014) · British Journal of Haematology · doi:10.1111/bjh.13042 · Cited by 33
Novel agents for primary central nervous system lymphoma: evidence and perspectives
Illerhaus, G., Schorb, E., & Kasenda, B. (2018) · Blood · doi:10.1182/blood-2018-01-791558 · Cited by 33
Small-molecule PROTACs: Novel Agents for Cancer Therapy
Wan, Y., Yan, C., Gao, H. J., & Liu, T. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0340 · Cited by 33
Kuzu, B., Hepokur, C., Alagöz, M. A., Burmaoğlu, S., & Algül, Ö. (2022) · ChemistrySelect · doi:10.1002/slct.202103559 · Cited by 33
Molecular glues: enhanced protein-protein interactions and cell proteome editing
Weagel, E. G., Foulks, J. M., Siddiqui, A. Q., & Warner, S. L. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-022-02882-2 · Cited by 33
Cereblon neo-substrate binding mimics the recognition of the cyclic imide degron
Heim, C., Spring, A.-K., Kirchgäßner, S., Schwarzer, D., & Hartmann, M. D. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.01.051 · Cited by 25
Takano, N., Hiramoto, M., Yamada, Y., Kokuba, H., Tokuhisa, M., Hino, H., & Miyazawa, K. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02210-4 · Cited by 33
Hu, Z., Holzschuh, J., & Driever, W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134299 · Cited by 33
Murayama, N., van Beuningen, R., Suemizu, H., Guguen‐Guillouzo, C., Shibata, N., Yajima, K., Utoh, M., Shimizu, M., Chesné, C., Nakamura, M., et al. (2014) · Chemical Research in Toxicology · doi:10.1021/tx4004374 · Cited by 33
Shen, M., Zhang, Y., Saba, N. S., Austin, C. P., Wiestner, A. U., & Auld, D. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075252 · Cited by 33
Millrine, D., Miyata, H., Tei, M., Dubey, P. K., Nyati, K. K., Nakahama, T., Gemechu, Y., Ripley, B., & Kishimoto, T. (2016) · International Immunology · doi:10.1093/intimm/dxw005 · Cited by 33
Xiao, D., Wang, Y.-J., Hu, X., Kan, W., Zhang, Q., Jiang, X., Zhou, Y., Li, J. X., & Lu, W. P. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.035 · Cited by 33
Immunomodulatory drugs in the treatment of multiple myeloma
Abe, Y., & Ishida, T. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz083 · Cited by 33
Unbiased mapping of cereblon neosubstrate landscape by high-throughput proteomics
Steger, M., Nishiguchi, G., Wu, Q., Schwalb, B., Shashikadze, B., McGowan, K., Actis, M., Aggarwal, A., Shi, Z., Price, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62829-0 · Cited by 32
Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders
Bouvier, C., Lawrence, R., Cavallo, F., Xolalpa, W., Jordan, A. M., Hjerpe, R., & Rodríguez, M. S. (2024) · Cells · doi:10.3390/cells13070578 · Cited by 32
PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications
Pravin, N., & Jóźwiak, K. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116837 · Cited by 32
Yamshon, S., & Ruan, J. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00536-6 · Cited by 32
Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
Mogollón, P., Díaz-Tejedor, A., Algarín, E. M., Paíno, T., Garayoa, M., & Ocio, E. M. (2019) · Cells · doi:10.3390/cells8111432 · Cited by 32
Thalidomide interaction with inflammation in idiopathic pulmonary fibrosis
Dsouza, N. N., Alampady, V., Baby, K., Maity, S., Byregowda, B. H., & Nayak, Y. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01193-1 · Cited by 32
Auxin-Inducible Degron System: An Efficient Protein Degradation Tool to Study Protein Function
Phanindhar, K., & Mishra, R. K. (2023) · BioTechniques · doi:10.2144/btn-2022-0108 · Cited by 32
Gunasekaran, P., Hwang, Y. S., Lee, G., Park, J., Kim, J. G., La, Y. K., Park, N. Y., Kothandaraman, R., Yim, M. S., Choi, J., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01493 · Cited by 32
de Jong, E., van Beek, L., & Piersma, A. H. (2014) · Reproductive Toxicology · doi:10.1016/j.reprotox.2014.03.012 · Cited by 32
McGraw, K. L., Basiorka, A. A., Johnson, J., Clark, J., Cáceres, G., Padron, E., Heaton, R., Ozawa, Y., Wei, S., Sokol, L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114249 · Cited by 32
Immediate and long-term consequences of vascular toxicity during zebrafish development
Tal, T. L., McCollum, C. W., Harris, P. S., Olin, J. K., Kleinstreuer, N., Wood, C. E., Hans, C., Shah, S. K., Merchant, F. A., Bondesson, M., et al. (2014) · Reproductive Toxicology · doi:10.1016/j.reprotox.2014.05.014 · Cited by 32
Chemical proteomic strategies for the discovery and development of anticancer drugs
Liu, Y., & Guo, M. (2013) · PROTEOMICS · doi:10.1002/pmic.201300261 · Cited by 32
Eichner, R., Fernández‐Sáiz, V., Targosz, B., & Bassermann, F. C. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.06.001 · Cited by 32
ZeOncoTest: Refining and Automating the Zebrafish Xenograft Model for Drug Discovery in Cancer
Cornet, C., Dyballa, S., Terriente, J., & Giacomo, V. D. (2019) · Pharmaceuticals · doi:10.3390/ph13010001 · Cited by 32
Detection of Thalidomide Embryotoxicity by In Vitro Embryotoxicity Testing Based on Human iPS Cells
Aikawa, N., Kunisato, A., Nagao, K., Kusaka, H., Takaba, K., & Ohgami, K. (2014) · Journal of Pharmacological Sciences · doi:10.1254/jphs.13162fp · Cited by 32
Central Neurotoxicity of Immunomodulatory Drugs in Multiple Myeloma
Patel, U., Mir, M. A., Sivik, J. M., Raheja, D., Pandey, M. K., & Talamo, G. (2015) · Hematology Reports · doi:10.4081/hr.2015.5704 · Cited by 32
Jonasova, A., Bokorova, R., Polak, J., Vostry, M., Kostecka, A., Hajkova, H., Neuwirtova, R., Siskova, M., Sponerova, D., Cermak, J., et al. (2015) · European Journal of Haematology · doi:10.1111/ejh.12457 · Cited by 31
Structural Dynamics of the Cereblon Ligand Binding Domain
Hartmann, M. D., Boichenko, I., Coles, M., Lupas, A. N., & Hernandez Alvarez, B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0128342 · Cited by 31
“The ubiquitin ligase activity of this complex is altered by thalidomide binding to cereblon [1], and also lenalidomide and pomalidomide were shown to bind to cereblon, competing for the same binding site [6].”
BackgroundLin, J., Chen, Z., Zhang, D., Zhang, N., Chen, H., & Guo, D. (2025) · Macromolecular Rapid Communications · doi:10.1002/marc.202401051 · Cited by 31
Lee, K. M., Yang, S., Choi, J., & Park, C. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.523423 · Cited by 31
Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond
Guirguis, A. A., & Ebert, B. L. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.10.004 · Cited by 31
Dimopoulos, K., Munch‐Petersen, H. F., Eskelund, C. W., Sjø, L. D., Ralfkiaer, E. M., Gimsing, P., & Grønbæk, K. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1466290 · Cited by 31
Design, Synthesis, and Biological Evaluation of Lysine Demethylase 5 C Degraders
Iida, T., Itoh, Y., Takahashi, Y., Yamashita, Y., Kurohara, T., Miyake, Y., Oba, M., & Suzuki, T. (2021) · ChemMedChem · doi:10.1002/cmdc.202000933 · Cited by 31
Self-citationGenetic Susceptibility to Drug Teratogenicity: A Systematic Literature Review
Gomes, J. D. A., Olstad, E. W., Kowalski, T. W., Gervin, K., Vianna, F. S. L., Schüler‐Faccini, L., & Nordeng, H. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.645555 · Cited by 31
Progress of small molecules for targeted protein degradation: PROTACs and other technologies
Zhao, H., Xin, M., & Zhang, S. (2023) · Drug Development Research · doi:10.1002/ddr.22026 · Cited by 31
An overview of PROTACs targeting MDM2 as a novel approach for cancer therapy
Li, H., Cai, X., Yang, X., & Zhang, X. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116506 · Cited by 31
The dark side of cohesin: The carcinogenic point of view
Mannini, L., & Musio, A. (2011) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2011.07.004 · Cited by 31
Sardnal, V., Rouquette, A., Kaltenbach, S., Bally, C., Chesnais, V., Leschi, C., Adès, L., Santini, V., Park, S., Toma, A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.59 · Cited by 31
Use of Zebrafish in Chemical Biology and Drug Discovery
Das, B. C., McCormick, L., Thapa, P., Karki, R., & Evans, T. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.170 · Cited by 31
A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands
Boichenko, I., Deiss, S., Bär, K., Hartmann, M. D., & Alvarez, B. H. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01735 · Cited by 31
IMiD compounds affect CD34+ cell fate and maturation via CRBN-induced IKZF1 degradation
Li, S., Fu, J., Wang, H., Ma, H., Xu, X., Yang, Y.-G., Deng, S., Mapara, M. Y., & Lentzsch, S. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017010348 · Cited by 30
Bauer, K., Berger, D., Zielinski, C. C., Valent, P., & Grunt, T. W. (2018) · Oncotarget · doi:10.18632/oncotarget.25474 · Cited by 31
Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity
Fujiwara, Y., Sun, Y., Torphy, R. J., He, J., Yanaga, K. K., Edil, B. H., Schulick, R. D., & Zhu, Y. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1781 · Cited by 31
AMPK is down‐regulated by the CRL4A‐CRBN axis through the polyubiquitination of AMPKα isoforms
Kwon, E., Li, X., Deng, Y., Chang, H. W., & Kim, D. Y. (2019) · The FASEB Journal · doi:10.1096/fj.201801766rrr · Cited by 31
The application of ubiquitin ligases in the PROTAC drug design
Chen, Y., & Jin, J. (2020) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmaa053 · Cited by 31
Unifying Catalysis Framework to Dissect Proteasomal Degradation Paradigms
Rodriguez-Rivera, F. P., & Levi, S. M. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00389 · Cited by 30
Dual-site molecular glues for enhancing protein-protein interactions of the CDK12-DDB1 complex
Zhang, Z., Li, Y., Yang, J., Li, J., Lin, X., Liu, T., Yang, S., Lin, J., Xue, S., Yu, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50642-0 · Cited by 30
Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41
Basiorka, A. A., McGraw, K. L., Ceuninck, L. D., Griner, L. N., Zhang, L., Clark, J., Cáceres, G., Sokol, L., Komrokji, R. S., Reuther, G. W., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1756 · Cited by 30
Spironolactone‐induced XPB degradation depends on CDK7 kinase and SCFFBXL18 E3 ligase
Ueda, M., Matsuura, K., Kawai, H., Wakasugi, M., & Matsunaga, T. (2019) · Genes to Cells · doi:10.1111/gtc.12674 · Cited by 30
Kim, M., Min, Y., Shim, J., Chun, E., & Lee, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02203 · Cited by 30
Targeting the E3 ubiquitin ligases DCAF15 and cereblon for cancer therapy
Nguyen, K. M., & Busino, L. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.03.007 · Cited by 30
Construction of an IMiD-based azide library as a kit for PROTAC research
Liu, H., Sun, R., Ren, C., Qiu, X., Yang, X., & Jiang, B. (2020) · Organic & Biomolecular Chemistry · doi:10.1039/d0ob02120b · Cited by 30
Immunoproteasome Function in Normal and Malignant Hematopoiesis
Santamaría, N. T., Ebstein, F., Heidel, F. H., & Krüger, E. (2021) · Cells · doi:10.3390/cells10071577 · Cited by 30
Selective degradation-inducing probes for studying cereblon (CRBN) biology
Powell, C. E., Du, G., Bushman, J. W., He, Z., Zhang, T., Fischer, E. S., & Gray, N. S. (2021) · RSC Medicinal Chemistry · doi:10.1039/d0md00382d · Cited by 30
Discovery of the First Examples of Threonine Tyrosine Kinase PROTAC Degraders
Lu, J., Huang, Y.-J., Huang, J., He, R. R., Huang, M., Lu, X., Xu, Y., Zhou, F., Zhang, Z., & Ding, K. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01768 · Cited by 30
PROTACs in gastrointestinal cancers
Chen, Y., Yang, Q., Xu, J., Tang, L., Zhang, Y., Du, F., Zhao, Y., Wu, X., Li, M., Shen, J., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.10.012 · Cited by 30
Spontaneous Chirality Evolved at the Au–Ag Interface in Plasmonic Nanorods
Sa, J., Hu, N., Heyvaert, W., Gordon, K. V., Li, H., Wang, L., Bals, S., Liz‐Marzán, L. M., & Ni, W. (2023) · Chemistry of Materials · doi:10.1021/acs.chemmater.3c01044 · Cited by 30
Feng, Y., Hu, X., & Wang, X. (2024) · Biomarker Research · doi:10.1186/s40364-024-00638-1 · Cited by 30
Expanding role of lenalidomide in hematologic malignancies
Ghosh, N., Grunwald, M. R., Fasan, O. O., & Bhutani, M. (2015) · Cancer Management and Research · doi:10.2147/cmar.s81310 · Cited by 31
Metadata
- Authors
- Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H.
- Affiliations
- Tokyo Institute of Technology (JP)
- Tohoku University (JP)
- Astellas Pharma (Japan) (JP)
- Corresponding author
- Ito, Takumi
- Ando, Hideki
- Handa, Hiroshi
- Venue
- Science
- Published
- 2010-03-12
- Volume
- 327
- Issue
- 5971
- Pages
- 1345-1350
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1997952190
- Cited by
- 2,136
- References
- 36
- Citations by year
- 2026: 141 · 2025: 189 · 2024: 189 · 2023: 174 · 2022: 179 · 2021: 169 · 2020: 171 · 2019: 120 · 2018: 126 · 2017: 104 · 2016: 100 · 2015: 114 · 2014: 99 · 2013: 103 · 2012: 67
- FWCI
- 74.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Developmental Biology › Congenital limb and hand anomalies
- Keywords
- thalidomide, teratogenicity, cereblon, E3 ubiquitin ligase, DDB1, CUL4A, limb malformations, FGF8, limb outgrowth, ubiquitination, zebrafish, chick embryo, drug repurposing
- MeSH terms
- Animals, Carrier Proteins, Chick Embryo, DNA-Binding Proteins, Embryo, Nonmammalian, Fibroblast Growth Factors, Forelimb, HeLa Cells, Humans, Peptide Hydrolases, Teratogens, Thalidomide, Zebrafish, Gene Expression Regulation, Developmental, Zebrafish Proteins, Ubiquitin-Protein Ligases, Cullin Proteins, Embryonic Development, Adaptor Proteins, Signal Transducing, Mutant Proteins, Ubiquitination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.